No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
354 |
4. Check minimum number of eventsNone |
354 |
5. Include endpointsNone |
354 |
6. Filter based on genotype QC (FinnGen only) |
316 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D10
- Name in latin
- Neoplasma benignum nasopharyngis
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Nasopharynx
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm of mouth and pharynx
- Benign neoplasms
- Neoplasms
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1716 | 784 | 921 |
| Only index persons | 1545 | 733 | 812 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.03 |
| Only index persons | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 52.07 | 54.78 | 49.75 |
| Only index persons | 51.34 | 54.20 | 48.77 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 316 | 163 | 153 |
| Unadjusted period prevalence (%) | 0.06 | 0.06 | 0.07 |
| Median age at first event (years) | 57.01 | 55.38 | 58.73 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 333
- Matched controls
- 3330
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D10.6
ICD-10 Finland
Benign neoplasm: Nasopharynx
4503599627370496.0
307.7
302
*
UDH02
NOMESCO Finland
Rhinopharyngoscopy
12.4
93.1
110
127
EMA30
NOMESCO Finland
Biopsy of rhinopharynx
283.6
69.1
68
*
EMB30
NOMESCO Finland
Adenotomy
20.7
47.2
37
20
UDQ12
NOMESCO Finland
Flexible laryngoscopy
5.9
26.0
51
99
DHA10
NOMESCO Finland
Biopsy of cavity of nose
33.8
21.9
28
9
DCA20
NOMESCO Finland
Insertion of ventilating tube through tympanic membrane
8.1
18.1
25
33
21070
ICD-8 Finland
Benign neoplasm of buccal cavity and pharynx, Nasopharynx
+∞
17.9
17
*
2107A
ICD-9 Finland
Benign neoplasm of lip, oral cavity and pharynx, Nasopharynx
+∞
16.8
16
*
D14.0
ICD-10 Finland
Benign neoplasm: Middle ear, nasal cavity and accessory sinuses
19.5
14.9
22
12
H65.3
ICD-10 Finland
Chronic mucoid otitis media
6.7
14.8
24
38
H65.2
ICD-10 Finland
Chronic serous otitis media
16.4
14.6
23
15
J35.2
ICD-10 Finland
Hypertrophy of adenoids
12.8
13.8
24
20
WX408
NOMESCO Finland
General anesthesy, balanced
2.5
13.7
115
572
ENA10
NOMESCO Finland
Biopsy of pharynx
52.2
12.9
15
*
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
5.5
12.7
25
48
R01AD09
ATC
mometasone; nasal
2.2
11.9
174
1090
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
2.2
11.5
198
1317
UDC00
NOMESCO Finland
Ear microscopy
3.3
10.9
44
147
1290
FHL
Epipharyngoscopy
+∞
10.5
10
*
C11.9
ICD-10 Finland
Malignant neoplasm: Nasopharynx, unspecified
+∞
10.5
10
*
H66.0
ICD-10 Finland
Acute suppurative otitis media
3.3
10.2
40
131
DCA10
NOMESCO Finland
Paracentesis of tympanic membrane
9.6
10.2
20
22
R01BA52
ATC
pseudoephedrine, combinations; oral
2.2
10.0
114
636
ENB00
NOMESCO Finland
Excision or exploration of lesion of pharynx
102.8
9.5
10
*
EMB10
NOMESCO Finland
Tonsillectomy
4.4
9.3
24
58
EP1DG
NOMESCO Finland
Very extensive examination of soft tissue of neck with high intesity magnet
19.3
9.0
13
7
WX105
NOMESCO Finland
Surface analgesia on skin or mucosa
2.8
8.9
49
195
R01AD08
ATC
fluticasone; nasal
2.1
8.6
108
619
J33.0
ICD-10 Finland
Polyp of nasal cavity
4.7
8.5
20
45
Z01.1
ICD-10 Finland
Examination of ears and hearing
2.4
8.4
64
299
DM1BD
NOMESCO Finland
Extensive CT of paranasal sinuses and face area
34.3
8.1
10
*
J39.2
ICD-10 Finland
Other diseases of pharynx
10.4
8.1
15
15
J34.2
ICD-10 Finland
Deviated nasal septum
3.3
7.9
31
101
H92.0
ICD-10 Finland
Otalgia
3.3
7.9
31
101
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
15.5
7.8
12
8
DHB10
NOMESCO Finland
Excision of lesion of internal nose
46.1
7.7
9
*
I63.3
ICD-10 Finland
Cerebral infarction due to thrombosis of cerebral arteries
4.1
7.6
21
54
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
2.5
7.5
49
212
C11.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of nasopharynx
+∞
7.3
7
*
J01.0
ICD-10 Finland
Acute maxillary sinusitis
2.0
7.2
90
510
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
3.3
7.2
28
91
H66.9
ICD-10 Finland
Otitis media, unspecified
3.0
7.2
32
113
EP1AE
NOMESCO Finland
Neck ultrasound examination
3.1
7.2
30
102
TPH04
NOMESCO Finland
Cathetrisation of vein
2.0
7.1
87
491
WZC00
NOMESCO Finland
Treatment plan or consultation
1.9
7.0
132
860
GD1AD
NOMESCO Finland
Thorax CT examination
2.9
7.0
33
120
J01CA04
ATC
amoxicillin; systemic
2.2
7.0
275
2277
R04.0
ICD-10 Finland
Epistaxis
2.7
6.7
37
147
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.8
6.5
176
1275
J02AC01
ATC
fluconazole; systemic
1.8
6.3
127
839
Z2221
NOMESCO Finland
Medical doctor
1.9
6.3
101
621
8010/3-C11.9
ICD-O-3
Carcinoma, NOS, of nasopharynx, NOS
+∞
6.3
6
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.9
6.3
102
631
UDM02
NOMESCO Finland
Sinoscopy
5.5
6.2
17
32
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
8.8
6.1
12
14
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
2.6
6.1
35
142
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
232
1695
2.22
10.04
11.5
10.4
4.17
4.15
e9/l
0.05
189
1485
95
523
2.14
8.39
2.1
2.0
—
—
—
0
0
25
77
3.43
6.98
1.2
1.2
—
—
—
0
0
29
100
3.08
6.77
2.3
1.7
—
—
—
0
0
188
1382
1.83
6.70
6.8
6.6
1.22
1.21
mmol/l
0.18
177
1285
73
400
2.06
6.37
1.8
1.9
—
—
—
0
0
29
105
2.93
6.23
2.6
1.9
—
—
—
0
0
200
1524
1.78
6.07
8.3
7.3
1.22
1.21
mmol/l
0.17
175
1315
29
111
2.77
5.64
4.1
3.2
—
—
—
0
0
13
23
5.83
5.11
1.6
1.1
—
—
—
0
0
81
495
1.84
5.05
2.2
2.3
2.28
2.30
g/l
0.19
75
451
186
1440
1.66
4.88
17.9
13.9
1.27
1.25
inr
0.23
152
1202
52
289
1.95
4.30
2.1
2.1
334.39
375.35
nmol/l
0.71
46
266
80
511
1.74
4.25
4.6
3.4
0.82
0.81
mmol/l
0.08
75
484
91
604
1.70
4.21
5.9
4.0
734.75
339.15
ng/l
0.53
69
478
214
1753
1.62
4.19
6.3
5.2
6.86
6.73
mmol/l
0.42
205
1666
169
1310
1.59
4.18
5.7
4.9
35.48
35.51
g/l
0.03
159
1236
63
378
1.82
4.12
1.8
2.0
—
—
—
0
0
36
179
2.13
4.02
1.7
1.6
—
—
—
0
0
171
1338
1.57
4.00
2.5
2.2
96.58
96.23
pmol/l
0.03
90
694
62
375
1.80
3.95
5.7
4.7
216.77
240.33
u/l
2.14
62
351
250
2160
1.63
3.64
6.4
4.5
13.69
12.21
mm/h
0.79
235
2005
80
533
1.66
3.60
2.2
2.4
11.89
12.97
umol/l
0.75
74
492
19
76
2.59
3.44
1.3
1.3
—
—
—
0
0
71
464
1.67
3.43
2.2
2.4
19.89
22.41
%
1.11
65
431
108
785
1.56
3.37
2.5
2.2
2.61
3.01
mg/l
1.05
91
679
166
1342
1.47
3.04
3.4
2.9
119.42
125.58
ug/l
0.13
155
1236
18
75
2.48
3.02
2.8
3.5
1.57
2.44
index
—
7
48
248
2178
1.54
2.98
5.3
4.3
14.91
14.80
pmol/l
0.26
228
1977
162
1314
1.45
2.86
2.7
2.5
77.54
76.41
nmol/l
0.18
145
1168
101
751
1.50
2.76
2.8
2.3
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
19
85
2.31
2.76
2.1
2.5
0.29
0.39
iu/ml
0.75
12
41
5
6
8.43
2.76
1.0
1.5
—
—
—
0
0
10
29
3.52
2.71
1.6
1.2
—
—
—
0
0
105
791
1.48
2.69
3.9
3.0
321.70
347.43
umol/l
2.08
97
693
12
43
2.86
2.67
1.1
1.5
0.43
46.49
nmol/l
0.49
12
37
75
527
1.55
2.66
1.7
1.7
1036.99
1238.82
nmol/l
1.04
55
396
90
660
1.50
2.62
1.8
1.8
1.06
1.42
mg/l
1.19
75
520
20
96
2.15
2.48
1.5
1.6
—
—
—
0
0
250
2234
1.48
2.45
11.8
8.5
80.32
81.45
u/l
0.11
241
2119
77
555
1.50
2.42
1.4
1.4
33.97
33.63
iu/ml
0.01
26
184
126
1017
1.38
2.13
4.2
3.3
32.32
33.09
u/l
0.05
120
968
163
1377
1.36
2.06
3.1
2.8
—
—
estimate
—
0
0
11
44
2.55
2.03
1.0
1.1
—
26.20
—
0
10
59
419
1.50
1.99
4.8
5.0
1.00
1.04
mmol/l
0.53
54
391
51
351
1.53
1.99
9.0
8.3
1.45
1.02
mmol/l
0.38
42
299
67
490
1.46
1.95
1.6
1.5
—
—
—
0
0
13
58
2.29
1.93
1.6
1.6
—
—
—
0
0
69
509
1.45
1.92
3.2
3.1
0.76
0.94
e6/l
0.33
41
268
14
65
2.20
1.91
1.6
1.6
—
—
—
0
0
21
115
1.88
1.87
2.0
2.1
142.30
364.50
ug/l
2.11
21
107
5
12
4.21
1.83
1.6
1.1
—
—
—
0
0
64
475
1.43
1.73
3.3
3.2
3.29
1.95
e6/l
0.38
35
238
106
857
1.35
1.72
3.7
3.2
0.36
0.45
e6/l
0.22
76
628
126
1047
1.33
1.70
4.0
3.4
2.37
2.36
mmol/l
0.57
111
945
10
40
2.55
1.68
1.4
1.6
—
—
—
0
0
15
76
2.02
1.67
1.0
1.2
—
—
—
0
0
11
50
2.24
1.58
1.6
1.6
—
—
—
0
0
116
961
1.32
1.58
2.9
2.7
58.75
64.88
u/l
0.38
106
892
59
440
1.41
1.56
7.5
7.3
104.49
104.09
mmol/l
0.24
59
440
109
897
1.32
1.55
2.0
1.7
20.92
21.01
nmol/l
0.02
90
741
28
178
1.63
1.54
2.4
2.5
27.94
17.26
au/ml
—
5
11
28
178
1.63
1.54
2.8
3.8
24.37
24.09
mmol/l
0.14
28
178
67
512
1.39
1.54
1.4
1.3
32.37
13.21
u/ml
0.50
14
199
17
94
1.85
1.50
1.6
1.6
—
—
—
0
0
15
80
1.92
1.47
1.1
1.2
—
—
—
0
0
5
16
3.16
1.44
2.0
1.8
—
—
—
0
0
5
16
3.16
1.44
1.2
1.2
—
—
—
0
0
5
16
3.16
1.44
2.0
1.8
—
—
—
0
0
5
16
3.16
1.44
2.0
1.8
—
—
—
0
0
5
16
3.16
1.44
2.0
1.8
—
—
—
0
0
292
2767
1.45
1.42
25.4
16.9
21.88
24.32
mg/l
0.71
261
2305
14
74
1.93
1.41
1.5
1.6
—
—
—
0
0
211
1911
1.28
1.39
4.0
3.6
45.42
52.42
u/l
0.54
202
1807
34
234
1.50
1.36
3.2
2.8
78.82
61.71
ml/min/173m2
0.90
11
103
9
42
2.17
1.34
1.7
1.8
—
—
—
0
0
20
121
1.69
1.34
4.6
3.1
25.16
24.78
mmol/l
0.34
20
114
34
235
1.50
1.33
1.4
1.4
—
—
—
0
0
34
235
1.50
1.33
2.7
3.7
81.86
84.22
ng/l
0.06
29
207
15
83
1.85
1.33
1.3
1.2
—
—
—
0
0
5
18
2.80
1.29
1.2
1.9
—
—
—
0
0
5
18
2.80
1.29
1.6
1.7
—
—
—
0
0
38
273
1.44
1.24
2.9
3.2
4.54
4.45
kpa
0.11
38
265
76
613
1.31
1.23
3.4
3.0
2.47
2.46
mmol/l
0.61
67
554
10
49
2.07
1.23
4.8
3.3
0.78
0.89
nmol/l
—
10
43
8
37
2.19
1.22
1.8
1.9
—
—
—
0
0
13
71
1.86
1.21
1.5
1.4
—
—
—
0
0
187
1687
1.25
1.20
3.7
3.0
—
—
—
0
0
48
365
1.37
1.15
5.6
5.2
30.56
31.76
%
0.36
32
235
31
218
1.47
1.14
5.1
2.8
5.28
5.17
kpa
0.33
31
213
84
694
1.28
1.14
1.4
1.3
0.81
1.47
u/ml
0.98
16
180
16
96
1.70
1.12
1.4
1.7
40.25
40.36
nmol/l
0.01
16
91
17
104
1.67
1.11
1.3
1.2
—
—
—
0
0
136
1197
1.23
1.06
4.6
4.0
31.36
87.21
ng/l
0.66
100
895
14
83
1.72
1.03
1.4
1.2
—
—
—
0
0
9
50
1.82
0.97
1.4
1.4
—
—
—
0
0
26
183
1.46
0.97
1.1
1.2
31.74
130.55
u/ml
—
7
73
13
77
1.72
0.96
2.5
2.4
82.90
71.90
ug/min
—
8
45
14
85
1.68
0.96
1.4
1.2
—
3.29
—
0
11
114
995
1.22
0.95
3.5
3.3
1371.76
1298.07
ng/l
0.09
105
849
272
2590
1.27
0.94
7.1
5.4
1.85
1.96
mu/l
0.75
257
2372
14
86
1.66
0.92
1.4
1.2
—
7.97
—
0
15
29
211
1.41
0.92
8.2
8.2
23.62
24.85
mmol/l
1.10
29
211
6
28
2.16
0.92
3.2
2.3
—
—
—
0
0
6
29
2.09
0.89
1.3
1.2
—
—
—
0
0
6
29
2.09
0.89
1.8
1.8
—
—
—
0
0
6
29
2.09
0.89
1.8
1.8
—
—
—
0
0
6
29
2.09
0.89
1.8
1.8
—
—
—
0
0
15
95
1.61
0.89
2.2
3.9
1.76
2.74
ratio
—
10
55
76
640
1.24
0.88
1.8
1.8
108621172.95
21627052.96
pmol/l
0.36
58
541
13
80
1.65
0.86
1.9
1.7
—
—
—
0
0
282
2707
1.27
0.83
6.0
5.4
6.11
6.01
mmol/l
0.53
259
2475
23
164
1.43
0.82
1.3
1.4
—
—
—
0
0
29
218
1.36
0.78
1.6
1.6
—
—
—
0
0
77
659
1.22
0.77
5.8
4.3
1.02
1.02
kg/l
0.00
56
432
41
327
1.29
0.75
4.8
4.5
3.34
43.28
ug/l
1.01
34
275
290
2801
1.27
0.75
6.5
6.1
2.60
2.67
mmol/l
0.63
265
2586
18
125
1.47
0.74
1.4
1.3
—
—
—
0
0
7
39
1.81
0.73
1.1
1.2
—
—
—
0
0
42
339
1.27
0.71
11.2
7.3
—
—
—
0
0
5
27
1.86
0.68
1.8
1.3
—
—
—
0
0
5
27
1.86
0.68
2.2
1.6
972.20
570.33
e6/l
—
5
21
14
95
1.49
0.65
1.6
2.5
94.21
90.47
%
0.23
14
90
277
2674
1.21
0.63
8.2
6.8
40.42
39.75
mmol/mol
0.57
260
2499
5
30
1.68
0.61
1.6
1.3
696.20
330.04
u/l
—
5
30
5
30
1.68
0.61
2.0
1.7
—
—
—
0
0
8
51
1.58
0.61
1.5
1.5
—
—
—
0
0
10
64
1.58
0.59
1.5
1.5
—
—
—
0
0
6
37
1.63
0.56
2.5
3.9
—
—
—
0
0
6
39
1.55
0.53
1.2
1.1
—
—
—
0
0
12
83
1.46
0.52
2.0
1.4
—
—
—
0
0
168
1576
1.13
0.52
5.7
4.1
0.00
0.94
estimate
0.50
20
323
6
40
1.51
0.52
1.2
1.3
—
—
—
0
0
11
75
1.48
0.51
1.1
1.1
—
20.89
—
0
9
12
85
1.43
0.47
1.4
1.3
—
—
—
0
0
164
1544
1.12
0.46
5.4
4.0
0.00
0.00
estimate
-0.00
27
340
5
31
1.62
0.43
1.6
3.0
1003.40
829.03
mg
—
5
31
298
2919
1.20
0.43
17.7
12.7
24.81
25.97
u/l
0.71
287
2840
10
70
1.44
0.42
1.8
1.5
—
—
—
0
0
80
878
0.88
0.41
4.0
3.4
0.00
0.09
estimate
0.52
22
287
0
16
0.00
0.41
0.0
2.3
—
103.94
—
0
16
5
35
1.43
0.39
1.2
1.1
—
—
—
0
0
112
1041
1.11
0.39
5.6
4.1
15.05
10.07
mg/mmol
0.30
74
660
21
257
0.80
0.38
2.3
2.2
—
—
—
0
0
164
1558
1.10
0.37
5.5
4.0
0.00
4.68
estimate
0.50
27
347
31
263
1.20
0.37
2.5
2.2
3.56
3.42
ratio
0.20
25
219
42
367
1.17
0.37
1.3
1.4
—
—
—
0
0
6
45
1.34
0.34
1.7
1.7
97.38
50.37
ug/l
—
6
37
6
45
1.34
0.34
1.2
1.4
—
—
—
0
0
23
192
1.21
0.33
2.0
2.0
3.37
3.43
mmol/l
0.09
18
146
20
238
0.83
0.30
2.1
2.0
—
—
—
0
0
106
997
1.09
0.29
5.8
5.5
3.65
2.59
ug/l
0.40
94
893
12
94
1.29
0.28
1.9
1.6
—
—
—
0
0
65
600
1.10
0.26
3.8
3.1
0.74
0.82
ug/l
0.28
41
375
10
77
1.31
0.26
1.1
1.6
—
—
—
0
0
112
1063
1.08
0.25
4.5
3.4
7.55
7.64
mmol/l
0.07
92
890
85
798
1.09
0.24
4.6
4.6
22.43
22.06
%
0.09
43
375
129
1234
1.07
0.23
2.0
2.0
1.41
1.39
mmol/l
0.11
99
1025
5
38
1.32
0.23
1.2
1.3
6.30
7.78
mmol/l
—
5
27
304
3004
1.14
0.23
37.3
25.7
4.44
4.49
e12/l
0.79
299
2944
83
879
0.93
0.22
6.2
4.1
0.00
0.01
estimate
0.50
24
321
0
11
0.00
0.21
0.0
4.3
—
4.70
—
0
11
0
11
0.00
0.21
0.0
4.3
—
9.97
—
0
11
11
89
1.24
0.21
1.4
1.4
335.00
279.04
ug/g
—
6
54
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
9.43
—
0
14
7
61
1.15
0.17
2.0
2.5
7.01
8.92
pmol/l
—
7
61
268
2643
1.07
0.17
4.9
4.5
1.33
1.30
mmol/l
0.25
238
2421
115
1186
0.95
0.13
5.3
4.0
0.00
0.02
estimate
0.88
22
301
274
2710
1.06
0.13
24.6
16.5
79.86
79.71
ml/min/173m2
0.04
256
2525
11
95
1.16
0.12
1.1
1.1
1.42
1.55
g/l
0.96
11
95
13
146
0.89
0.10
1.8
1.5
0.24
0.35
mg/l
—
5
61
6
70
0.85
0.07
1.2
1.4
—
—
—
0
0
8
78
1.03
0.07
1.5
1.6
970.76
901.15
mu/l
—
8
63
11
99
1.11
0.06
1.1
1.2
0.86
0.90
g/l
0.48
11
99
276
2744
1.03
0.05
5.9
5.3
1.43
1.45
mmol/l
0.42
252
2526
277
2756
1.03
0.04
5.9
5.4
4.52
4.58
mmol/l
0.42
255
2554
32
332
0.96
0.04
4.5
3.6
—
—
—
0
0
14
135
1.04
0.00
1.1
1.0
—
—
—
0
0
12
115
1.05
0.00
2.7
2.1
—
—
—
0
0
5
52
0.96
0.00
1.0
1.5
—
—
—
0
0
5
52
0.96
0.00
1.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.2
—
1.31
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
9
98
0.92
-0.00
2.9
2.1
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
8
0.00
-0.00
0.0
1.1
—
124.75
—
0
8
8
79
1.01
-0.00
1.4
1.7
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CD2_BENIGN_NASOPHARYNX and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_NASOPHARYNX | 1.468 [1.14, 1.89] | 0.003 |
| Birth year | 0.988 [0.98, 1.0] | 0.01 |
During the follow-up period (1.1.1998 — 31.12.2019), 99 out of 608 females with CD2_BENIGN_NASOPHARYNX died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_NASOPHARYNX | 1.524 [1.23, 1.89] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 145 out of 638 males with CD2_BENIGN_NASOPHARYNX died.
Mortality risk
Mortality risk for people of age
years, who have CD2_BENIGN_NASOPHARYNX.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.144% | 0.226% |
| 5 | 0.644% | 1.578% |
| 10 | 1.517% | 4.198% |
| 15 | 2.925% | 8.015% |
| 20 | 5.201% | 13.646% |
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_NASOPHARYNX – Benign neoplasm: Nasopharynx
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data